FDA EIR - PATH - April 16, 2009

An FDA GLP surveillance inspection of Vet Path Services, Inc., a contract histopathology firm located in Mason, OH, was conducted from April 13 to April 16, 2009. This represented the initial FDA inspection for the company, which provides pathology, histology, and off-site necropsy services to various clients. The inspection aimed to assess the firm's adherence to Good Laboratory Practice regulations, in accordance with CP 7348.808. During the four-day inspection, a comprehensive review of the company's operations was performed, including an examination of their quality assurance processes, facility operations, Standard Operating Procedures (SOPs), and computer systems utilized for study management and data handling. The FDA investigator reviewed pending study protocols and observed pathologists performing work related to ongoing studies. Significantly, the inspection concluded without the identification of any violations or objectionable conditions. Consequently, an FDA-483, which would typically list such observations, was not issued. No refusals were encountered, and no samples were collected. The inspection confirmed that Vet Path Services, Inc. was operating in compliance with the relevant regulatory frameworks, and no specific actions were required from the company by the FDA.